On September 14, 2020 Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, reported that results from ADVANCE, a Phase 1/2 study in metastatic castrate resistant prostate cancer (mCRPC), sponsored by the University of Oxford, will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) virtual congress (Press release, Vaccitech, SEP 14, 2020, View Source [SID1234565074]). The results, courtesy of the Jenner Institute, University of Oxford, include safety, T cell immunogenicity and individual PSA responses from 23 mCRPC patients who received VTP-800, a prime-boost immunotherapeutic regimen of ChAdOx and MVA targeting the oncofetal antigen, 5T4, in combination with the anti-PD-1 checkpoint inhibitor, nivolumab.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conferences Details:
Event: European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Virtual Congress 2020
Format: Poster 682P, Abstract #4172; Results from ADVANCE, a Phase I/II open-label non-randomised safety and efficacy study of the viral vectored
ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer
Presented by Dr. Mark Tuthill
Date: 17th September 2020